SEC Form 4 · accession 0001159036-26-000074
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — PRESIDENT AND CEO · Director
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 8:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2026 | M | 20,000 | $12.07 | A | 787,780 | D | |
| Common StockF2 | Jun 1, 2026 | S | 1,610 | $66.388 | D | 786,170 | D | |
| Common StockF3 | Jun 1, 2026 | S | 12,989 | $67.41 | D | 773,181 | D | |
| Common StockF4 | Jun 1, 2026 | S | 5,401 | $68.346 | D | 767,780 | D | |
| Common Stock | Jun 2, 2026 | M | 20,000 | $12.07 | A | 787,780 | D | |
| Common StockF5 | Jun 2, 2026 | S | 16,600 | $66.314 | D | 771,180 | D | |
| Common StockF6 | Jun 2, 2026 | S | 3,400 | $66.745 | D | 767,780 | D | |
| Common Stock | Jun 3, 2026 | M | 10,000 | $12.07 | A | 777,780 | D | |
| Common StockF7 | Jun 3, 2026 | S | 400 | $66.368 | D | 777,380 | D | |
| Common StockF8 | Jun 3, 2026 | S | 1,500 | $67.675 | D | 775,880 | D | |
| Common StockF9 | Jun 3, 2026 | S | 2,000 | $68.736 | D | 773,880 | D | |
| Common StockF10 | Jun 3, 2026 | S | 6,100 | $69.692 | D | 767,780 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF11 | $12.07 | Jun 1, 2026 | M | 20,000 | D | — | Feb 22, 2027 | Common Stock | 20,000 | 31,923 | D |
| Option to Purchase Common StockF11 | $12.07 | Jun 2, 2026 | M | 20,000 | D | — | Feb 22, 2027 | Common Stock | 20,000 | 11,923 | D |
| Option to Purchase Common StockF11 | $12.07 | Jun 3, 2026 | M | 10,000 | D | — | Feb 22, 2027 | Common Stock | 10,000 | 1,923 | D |
Explanation of responses
- F1The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- F10Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.120 to $70.050. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F11Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
- F2Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.840 to $66.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.840 to $67.830. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.840 to $68.820. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.630 to $66.625. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.630 to $67.180. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7Represents a weighted average sales price per share. The shares were sold at prices ranging from $66.000 to $66.770. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F8Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.090 to $68.000. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F9Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.